A5047516379- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Brain Metastases and Treatment
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Metastasis and carcinoma case studies
- Ovarian cancer diagnosis and treatment
- Pancreatic and Hepatic Oncology Research
- Nonmelanoma Skin Cancer Studies
Istanbul Medipol University
2015-2025
Pfizer (United States)
2024
Pfizer (United Kingdom)
2024
Roche (Switzerland)
2024
AstraZeneca (Brazil)
2024
Novartis (Switzerland)
2024
Weatherford College
2021-2024
Bursa Uludağ Üni̇versi̇tesi̇
2008-2023
Hacettepe University
2021
Bakırköy Psychiatric Hospital
2021
Background and Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but their use is associated with a spectrum of immune-related adverse events (irAEs), including endocrine disorders. This study aims to investigate the incidence, timing, treatment modalities, impact ICI-related side effects in patients. Materials Methods: retrospective analyzed 139 patients treated ICIs between 2016 2022. Data regarding irAEs, hypothyroidism, hyperthyroidism, hypophysitis,...
Background/Objectives: The study aimed to compare the treatment effectiveness of patients with locally advanced rectal cancer undergoing standard neoadjuvant therapy or total therapy. It also sought identify prognostic factors for disease-free survival and overall parameters predictive pathological complete response. Materials Methods: A retrospective analysis was conducted on 239 diagnosed between 2016 2022 at several medical centers in Turkey. Clinical data, including chemoradiotherapy...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with limited treatment options. Identifying reliable prognostic biomarkers crucial for risk stratification and therapeutic decision-making. This study investigates the significance of Claudin 18.2 (CLDN18.2), isocitrate dehydrogenase-1 (IDH1) expression, neutrophil-to-lymphocyte ratio (NLR) in patients unresectable PDAC receiving first-line chemotherapy. retrospective, single-center included 72 histologically confirmed...
Background and Objectives: Epithelial ovarian cancer (EOC) remains a significant global health challenge. While traditional prognostic factors are well established, emerging biomarkers continue to gain attention. Materials Methods: This retrospective study evaluated the impact of systemic inflammatory markers on progression-free survival (PFS) overall (OS) in 154 EOC patients. Pre-treatment neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte (PLR), index (SII) were calculated categorized...
Background: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies with no standardized treatment approach. Although platinum-based chemotherapy is considered the first-line therapy, overall survival (OS) and progression-free (PFS) remain limited. This study aims to evaluate clinical pathological characteristics of EP-NEC patients, their responses, outcomes. Methods: retrospective observational included 29 patients diagnosed followed between 2015 2024. Clinical...
Amaç: Hepatoselüler karsinom (HCC), dünya genelinde önemli bir sağlık sorunu olan karaciğer kanseridir. Çoğu hasta unrezektabl evrede tanı alır. Lokorejyonel tedaviler (LRT) ve sorafenib gibi sistemik tedaviler, HCC tedavisinde kullanılan yöntemlerdir. Bu çalışmada, LRT kombinasyonunun hastalarındaki etkinliği güvenilirliği retrospektif olarak araştırılmıştır. Gereç Yöntem: 2018-2023 yılları arasında İstanbul Medipol Üniversitesi Hastanesi'nde takip edilen 20 hastası çalışmaya dahil edildi....
Background/Objectives: This study aimed to investigate the prognostic and predictive significance of ATM expression in patients with metastatic non-small cell lung cancer (NSCLC) treated pembrolizumab. Methods: A retrospective analysis was conducted on 49 NSCLC who received first-line pembrolizumab as a single agent or combination chemotherapy. Immunohistochemistry used assess archival pathology specimens. Nuclear staining considered positive. categorized into low high groups based combined...
Background/Objectives: Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive malignancies with no standardized treatment approach. Although platinum-based chemotherapy is considered the first-line therapy, overall survival (OS) and progression-free (PFS) remain limited. This study aims to evaluate clinical pathological characteristics of EP-NEC patients, their responses, outcomes. Methods: retrospective observational included 29 patients diagnosed followed between 2015...
Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy and evaluated efficacy safety adding to ES-SCLC predictive factors as a real-life experience. This retrospective study included 55 who received front-line etoposide platin regimen ES-SCLC. We analyzed survival outcomes that may predict response survival. The objective rate (ORR)...
Based on the CheckMate 649 trial, nivolumab plus chemotherapy is recommended first-line treatment for HER2-negative unresectable advanced or metastatic gastric, gastroesophageal junction (GEJ), esophageal adenocarcinoma. This nationwide, multicenter, retrospective study evaluated real-world effectiveness of this regimen in Turkish patients and identified subgroups that may experience superior outcomes. Conducted across 16 oncology centers Turkey, retrospectively reviewed clinical charts...
The modified Early Warning Score (mEWS) is a triage instrument that promises to predict patient disposition and clinical outcome in emergency departments (EDs). We investigated whether mEWS can death, hospital admission, intensive care unit (ICU) in-hospital deaths Turkish setting.We conducted an ED-based prospective study of 309 patients who presented academic medical center. was recorded all on ED admission. A >4 used define at high-risk for the outcomes.Patients categorized as being...
Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the significance metastatic lymph ratio (MLNR) and compare it number metastasis pN3 cancer.We retrospectively analyzed 207 cancer who had undergone radical gastrectomy. Prognostic factors MLNR were evaluated by univariate multivariate analysis.An 0.75 found be best cut-off value prognosis (p = 0.001). significantly higher large-sized undifferentiated tumors,...
The objective of this multi-centre, real-world study was to examine the potential influence comprehensive molecular profiling on development treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated impact these informed choices patient outcomes.
The current study was designed to assess the response treatment, as well clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 2019, a total of 139 were histologically confirmed have cancer, NAC, subsequently received axillary surgery, retrospectively included this study. rates pathological complete (pCR) NAC significantly higher for HER2-positive triple-negative than luminal A HER2-negative (p = 0.013)....